Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

IN TIMI-36 have been studied in previous Phase 3 clinical trials.

Participants in the MERLIN TIMI-36 study received current standard therapy, with approximately 96 percent of patients on aspirin, approximately 89 percent on beta blockers and approximately 82 percent on statins. Approximately 59 percent of study participants received coronary angiography during their initial hospitalization.

Previously published data from the MERLIN TIMI-36 study has shown that Ranexa was safe in this population of patients with coronary artery disease, which included nearly 1,100 patients with prior heart failure.

Potential Diabetes Mechanism

Substantial published data suggest that the anti-ischemic effects of Ranexa result from the drug's activity to inhibit the late sodium current in cardiac cells. Preclinical work to identify the potential mechanism of action of Ranexa in diabetes has shown that ranolazine increased glucose stimulated insulin secretion in pancreatic islets. In separate experiments using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis.

These data could illustrate an underlying potential first in class mechanism of action for the statistically significant reductions in HbA1c levels observed with Ranexa in cardiovascular patients with diabetes from the Phase 3 CARISA (n=189 with angina and diabetes) and MERLIN TIMI-36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials.

In CARISA (Combination Assessment of Ranolazine in Stable Angina), Ranexa reduced HbA1c levels by an average of up to 0.7 percentage points in angina patients with diabetes. The reduction in HbA1c was not associated with increased hypoglycemia.

The Company plans to submit data from these new preclinical experiments for publication later this year.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular c
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 The Female Health ... an investor conference call to discuss its operating results ... 30, 2014 on Tuesday, December 2, 2014 at 11:00 ... report its operating results earlier the same day. ... the conference call by dialing 1-877-374-8416 (international participants dial ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
(Date:11/24/2014)... , Nov. 24, 2014  Pifflers United ... announced the release of results of a ... device, in the self-management of fibromyalgia pain. The ... of worst pain, very significant clinically meaningful pain ... 140 group members with fibromyalgia used ActiPatch® for ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... , ST. PAUL, Minn. , ... take ibuprofen may reduce their risk of developing Parkinson,s disease, according to ... Academy of Neurology ,s 62nd Annual Meeting in Toronto ... people who did not have Parkinson,s disease at the beginning of the ...
... , , CAGLIARI, Italy , Feb. ... than 4500 patients from six Italian EVEREST (European Vertebroplasty Research ... , Dr. P. Carpeggiani-Pisa, Dr. S. Masala-Roma , Dr. ... treating vertebral compression fractures (VCFs), finding that the procedure provides ...
Cached Medicine Technology:An Ibuprofen a Day Could Keep Parkinson's Disease Away 2Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures 2Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures 3Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures 4
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a ... great promotion for many products, especially the beautiful colored ... best choice with amazing discounts, up to 90% off. ... It is easy to buy colored wedding dresses in ... is also famous for delicate craftsmanship, elegant style and ...
(Date:11/23/2014)... November 23, 2014 Pro Ace Care, a ... it will now be providing an 8 year warranty on ... water tank installations went up due to the impending winter ... its customers of the premium service that the company provides. ... year warranty on John Wood and Bradford hot water tanks. ...
(Date:11/23/2014)... SUNDAY, Nov. 23, 2014 (HealthDay News) -- The holidays ... autism because sensory overload can trigger major meltdowns, an ... under the best of circumstances, but when you have ... Varleisha Gibbs, an occupational therapy professor at University of ... release. "It,s best to let your hosts or ...
(Date:11/23/2014)... show thanks to new and old customers, iFitDress.com has ... for weddings. Customers who need custom outfits can talk ... dress manufacturer, and it is among the ones which have ... long time. The CEO of this company says, "iFitDress.com is ... buy not only a beautiful dress, but also a piece ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, ... dresses. “If you are looking for gorgeous beach wedding ... possible. Here you can enjoy 70% off discounts and ... a big marriage ceremony is the most important dream ... dress is uppermost priority. Ophelia, one of customers, said, ...
Breaking Medicine News(10 mins):Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... pressure, two conditions rooted in genetics and environmental surroundings, ... determining// who is mostly likely to develop heart failure, ... Americans die from heart failure. ,Experts ... exist in who actually develops risk factors for the ...
... A recent study conducted on the pneumococcal conjugate vaccine, administered ... diseases, has helped reduce hospitalizations among children due to pneumonia. ... it is important for all U.S. children to get four ... in the age group of 2-5, who have missed out ...
... eat apples during pregnancy may protect their children from developing ... Netherlands and Scotland tracked dietary intake by nearly 2,000 pregnant ... airway development in more than 1,200 of their children five ... consumed and recorded by the pregnant women, the researchers found ...
... 7 th of April every year. ... World Health Organization. //The primary role of the World Health Day ... universal awareness. The theme for the year 2007 is, ... world governments, business sectors and other non- governmental organizations to ‘invest ...
... United Biotech is diversifying into the oncology segment starting ... an initial// investment of $3.4 million. ... oncology at its facility in Baddi, Himachal Pradesh (India). ... Blausiegel, a Brazilian company, for its entire range of ...
... nutrition in children could lead to confusion and a cut ... programs, warn researchers in this week’s BMJ. ,According ... emergencies has risen over the last twenty years, from an ... than 30 per year since 2000. In 2005, around 73 ...
Cached Medicine News:Health News:Race Takes Back Seat to Diabetes and High Blood Pressure 2Health News:Race Takes Back Seat to Diabetes and High Blood Pressure 3Health News:'Invest in Health, Build a Safer Future': World Health Day 2Health News:New Standards Could Cut Number of Malnourished Children on Feeding Programs 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
The SJM Sguin annuloplasty ring, a semi-rigid ring, is constructed of a one-piece solid core of ultra-high-weight polyethylene enclosed in a knitted polyester sewing cuff....
Medicine Products: